HELEN-Trio 011 | Can We Treat TNBC Without Anthracyclines? A promising phase III trial — but is it practice-changing? Part 1 — The Big Question Can we simplify neoadjuvant treatment for stage II–III TNBC by avoiding anthracyclines? Part 2 — The Good News Adding camrelizumab to docetaxel–carboplatin significantly improved pCR: 57.5% vs 45.4% (P = 0.014, one-sided). Part 3 — The Survival Question 2-year EFS: 89.7% vs 86.4% HR 0.67 (95% CI 0.34–1.33). Encouraging, but not statistically significant. Severe toxicity was manageable. Part 4 — Why NOT Practice-Changing? - No direct comparison with KEYNOTE-522. - Survival benefit remains unproven. - Anthracycline omission has not been proven noninferior. - Apparent safety advantages require direct comparison. My Take-Home: Improving pCR is encouraging. But before removing anthracyclines from a curative regimen, we need confidence that long-term outcomes are preserved. Promising de-escalation. Not yet practice-changing. 📖 Reference: Jiao D et al. HELEN-Trio 011. Annals of Oncology, 2026. DOI: doi.org/10.1016/j.annonc.202… #MVOnco #BreastCancer #TNBC #HELENTrio011 #Immunotherapy #OncologyResearch

Daraxonrasib: The FDA Label Controversy Part 1: The breakthrough — OS 13.2 vs 6.7 months. Why the FDA label sparked debate. Part 2: The controversial “OR” — evidence versus patient access. Part 3: The real-world gap — why most patients never reach second-line therapy. Part 4: The unanswered questions — frontline evidence, cost and clinical judgment. Take-home: A flexible label may improve access, but approval ≠ proven benefit for everyone. Subbiah & Kurzrock | Nature Reviews Clinical Oncology (2026) doi.org/10.1038/s41571-026-0…